> BioLineRx began enrollment in the triple combination arm of its phase 2a trial. Pancreatic cancer patients enrolled in the arm will receive BioLineRx’s BL-8040, Merck’s Keytruda and chemotherapy. Statement
> Arix Bioscience appointed Christian Schetter as entrepreneur in residence. Schetter was last seen leading Rigontec to its acquisition by Merck. Release
> The Bill & Melinda Gates Foundation provided funding to Evox Therapeutics. Evox will use the money to improve delivery of a nucleic acid-based anti-infective drug. Statement
> The FDA set Acacia Pharma’s PDUFA date at May 5. Acacia thinks it is on track to bring its treatment for postoperative nausea and vomiting to market in the first half of next year. Release
> Netris Pharma completed a phase 1 trial of its anti-netrin-1 blocking antibody. The trial encountered no dose-limiting toxicities and uncovered preliminary evidence of antitumor activity. Statement
> Affimed detailed plans to move AFM13 into a phase 2 lymphoma trial designed to set it up to win an accelerated approval for the innate cell engager. The trial is due to get underway in the first half of next year. Release